Haplotype analysis of the MDR1 flanking region in the dog breed Elo

Berliner und Munchener Tierarztliche Wochenschrift

Volumn 121, Issue 5-6, 2008, Pages 211-215

  Fecht, Silvia ^a   Wöhlke, Anne ^a   Distl, Ottmar ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Dog; Elo; Haplotype; MDR1; Old English sheepdog

Indexed keywords

ALLELE; ANIMAL; ARTICLE; BREEDING; DOG; DOG DISEASE; FEMALE; GENE; GENE DELETION; GENETICS; HAPLOTYPE; MALE; MULTIDRUG RESISTANCE;

ALLELES; ANIMALS; BREEDING; DOG DISEASES; DOGS; DRUG RESISTANCE, MULTIPLE; FEMALE; GENES, MDR; HAPLOTYPES; MALE; SEQUENCE DELETION;

CANIS FAMILIARIS;

EID: 44849105486     PISSN: 00059366     EISSN: None     Source Type: Journal    
DOI: 10.2376/0005-9366-121-211     Document Type: Article

References (20)

1. Baars C., T. Leeb, T. von Klopmann, A. Tipold, H. Potschka (2007): Allele-specific polymerase chain reaction diagnostic test for the functional MDR1 polymorphism in dogs. Vet. J., doi:10.1016/j.tvjl.2007.05.020.
2. Cordon-Cardo C., J. P. O'Brien, D. Casals, L. Rittmann-Grauer, J. L. Biedler, M. R. Melamed, J. R. Bertino (1989): Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A. 86, 695-698.
3. Fecht S., A. Wöhlke, H. Hamann, O. Distl (2007): Analysis of the canine mdr1-1Δ mutation in the dog breed Elo. J. Vet. Med. A 54, 401-505.
4. Fromm M. F. (2000): P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38, 69-74.
5. Fromm M. F. (2004): Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25, 423-429.
6. Geyer J., B. Döring, J. R. Godoy, A. Moritz, E. Petzinger (2005a): Development of a PCR-based diagnostic test detecting a nt230 (del4) MDR1 mutation in dogs: verification in a moxidectin-sensitive Australian Shepherd. J. Vet. Pharmacol. Therap. 28, 95-99.
7. Geyer J., B. Döring, J. R. Godoy, R. Leidolf, A. Moritz, E. Petzinger (2005b): Frequency of the nt230 (del4) MDR1 mutation in Collies and related dog breeds in Germany. J. Vet. Pharmacol. Therap. 28, 545-551.
8. Henik R. A., H. B. Kellum, S. A. Bentjen, K. L. Mealey (2006): Digoxin and mexiletine sensitivity in a Collie with the MDR1 mutation. J. Vet. Int. Med. 20, 415-417.
9. Kaufhold J., H. Hamann, O. Distl (2005): Population genetic analysis of the new dog breed Elo. Berl. Münch. Tierärztl. Wochenschr. 118, 67-75.
10. Kawabata A., Y. Momoi, M. Inoue-Murayama, T. Iwasaki (2005): Canine mdr1 gene mutation in Japan. J. Vet. Med. Sci. 67, 1103-1107.
11. Mealey K. L., S. A. Bentjen, J. M. Gay, G. H. Cantor (2001): Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11, 727-733.
12. Mealey K. L., N. C. Northrup, S. A. Bentjen (2003): Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J. Am. Vet. Med. Assoc. 223, 1453-1455.
13. Mealey K. L., K. A. Munyard, S. A. Bentjen (2005): Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of herding breed dogs living in Australia. Vet. Parasitol. 131, 193-196.
14. Mealey K. L., J. M. Gay, L. G. Martin, D. K. Waiting (2007): Comparison of the hypothalamic-pituitary-adrenal axis in MDR1-1Δ and MDR1 wildtype dogs. J. Vet. Emerg. Crit. Care 17, 61-66.
15. Neff M. W., K. R. Robertson, A. K. Wong, N. Safra, K. W. Broman, M. Slatkin, K. L. Mealey, N. C. Pedersen (2004): Breed distribution and history of canine mdr1-1Δ, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc. Natl. Acad. Sci. U.S.A. 101, 11725-11730.
16. Roulet A., O. Puel, S. Gesta, J.-F. Lepage, M. Drag, M. Soll, M. Alvinerie, T. Pineau (2003): MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur. J. Pharmacol. 460, 85-91.
17. Sartor L. L., S. A. Bentjen, L. Trepanier, K. L. Mealey (2004): Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity. J. Vet. Intern. Med. 18, 117-118.
18. Schinkel A. H. (1998): Pharmacological insights from P-glycoprotein knockout mice. Int. J. Clin. Pharmacol. Ther. 36, 9-13.
19. Wrede J., T. Schmidt (2003): OPTI-MATE Version 3.87. Ein Management-Programm zur Minimierung der Inzucht in gefährdeten Populationen. Programmbeschreibung. Institut für Tierzucht und Vererbungsforschung, Tierärztliche Hochschule Hannover.
20. Yas-Natan E., M. Shamir, S. Kleinbart, I. Aroch (2003): Doramectin toxicity in a collie. Vet. Rec. 153, 718-720.